Publication:
The Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillance

dc.contributor.authorLlorente, Francisco
dc.contributor.authorPérez-Ramírez, Elisa
dc.contributor.authorPerez-Olmeda, Mayte
dc.contributor.authorDafouz-Bustos, Desirée
dc.contributor.authorFernández-Pinero, Jovita
dc.contributor.authorMartínez-Cortés, Mercedes
dc.contributor.authorJiménez-Clavero, Miguel Ángel
dc.contributor.funderComunidad de Madrid (España)es_ES
dc.date.accessioned2023-12-19T20:58:33Z
dc.date.available2023-12-19T20:58:33Z
dc.date.issued2023-11-16
dc.description.abstractThe presence of SARS-CoV-2 antibodies was examined over 7 months in a population of essential service workers exposed during the first epidemic wave in Madrid (Spain). Results obtained with different serological assays were compared. Firstly, serum samples obtained in April 2020 were analyzed using eleven SARS-CoV-2 antibody detection methods, including seven ELISAs, two CLIAs and two LFAs. While all of the ELISA tests and the Roche eCLIA method showed good performance, it was poorer for the Abbott CLIA and LFA tests. Sera from 115 workers with serologically positive results in April were collected 2 and 7 months after the first sampling and were analyzed using five of the tests previously assessed. The results showed that while some ELISA tests consistently detected the presence of anti-SARS-CoV-2 antibodies even 7 months after first detection, other methods, such as the Abbott CLIA test, showed an important reduction in sensitivity for these mature antibodies. The sensitivity increased after establishing new cut-off values, calculated taking into account both recent and old infections, suggesting that an adjustment of assay parameters may improve the detection of individuals exposed to the infection.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis research was funded by the Madrid City Council (Specific epidemiological and health studies of COVID-19 to know the prevalence of the disease in essential operational sectors).es_ES
dc.format.number11es_ES
dc.format.page1360es_ES
dc.format.volume12es_ES
dc.identifier.citationPathogens. 2023 Nov 16;12(11):1360.es_ES
dc.identifier.doi10.3390/pathogens12111360es_ES
dc.identifier.issn2076-0817es_ES
dc.identifier.journalPathogens (Basel, Switzerland)es_ES
dc.identifier.pubmedID38003824es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16848
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/pathogens12111360es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCLIAes_ES
dc.subjectCOVID-19es_ES
dc.subjectELISAes_ES
dc.subjectLFAes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectSerologic assayses_ES
dc.titleThe Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillancees_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationd01866d4-34ba-4cd6-b995-3c4199bf0c59
relation.isAuthorOfPublication.latestForDiscoveryd01866d4-34ba-4cd6-b995-3c4199bf0c59

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
DetectionSARS-CoV-2Antibodies_2023.pdf
Size:
274.93 KB
Format:
Adobe Portable Document Format
Description: